AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

Bergwerk Dov sold $1.1M of TEVA

Bergwerk Dov (Interim Cheif Legal Officer) sold 26,260 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $41.72 ($1.10M total) across 2 trades on 2026-11-04.

Original reporting
SEC EDGAR · Bergwerk Dov
Published Nov 6, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Bearish
medium confidence
Mentioned
$TEVA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVABearishLow
01

Why it matters

The disclosed sale may influence short-term sentiment but is unlikely to affect long-term fundamentals.

02

Market read

Primary insider sale news with modest materiality; limited trading relevance.

03

What to watch

The sale was executed via an open-market transaction at $41.72, close to recent trading levels, suggesting limited urgency.

Relevance 6/10Novelty 5/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$TEVABearishMedium confidence
Context

Interim Chief Legal Officer Bergwerk Dov sold 26,260 shares for $1.095M, reducing his stake to 11,943 shares.

Expected impact

likely modest downward pressure as the market prices in the insider sell

Evidence & confidence

A C-level insider sold over $1M of stock; such sales often lead to short-term price weakness.

Market effects

Sector

Minimal impact on the broader pharmaceutical sector.

Regional

No significant regional effect.

Global

Limited to TEVA investors.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Individual
    Bergwerk Dov

    Interim Chief Legal Officer of TEVA

  • Company
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Global pharmaceutical company

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com